Nuvectis Pharma, Inc.

NasdaqCM:NVCT Stock Report

Market Cap: US$598.7m

Nuvectis Pharma Management

Management criteria checks 3/4

Nuvectis Pharma's CEO is Ron Bentsur, appointed in Jul 2020, has a tenure of 6.5 years. total yearly compensation is $2.59M, comprised of 25.3% salary and 74.7% bonuses, including company stock and options. directly owns 11.7% of the company’s shares, worth $70.04M. The average tenure of the management team and the board of directors is 6 years and 4.8 years respectively.

Key information

Ron Bentsur

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage25.26%
CEO tenure6yrs
CEO ownership11.7%
Management average tenure6yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Analysis Article • May 06

Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 09

We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 20

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 26

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 06

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Oct 03

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 31

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Sep 28

Nuvectis Pharma forms scientific advisory board for research and development of drugs

Nuvectis Pharma (NASDAQ:NVCT) said on Wednesday it had formed a Scientific Advisory Board that will help guide the company’s research and development strategy. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling studies.
Seeking Alpha • Aug 05

Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04

Nuvectis Pharma press release (NASDAQ:NVCT): Q2 GAAP EPS of -$0.28 misses by $0.04. Cash, cash equivalents, and short-term investments were $13.6 million as of June 30, 2022, compared to $5.7 million as of December 31, 2021. The increase of $7.9 million was primarily a result of the Company’s initial public offering in February 2022.
Seeking Alpha • Jul 27

Nuvectis Pharma declines 13%, announces $15.9M private placement

Nuvectis Pharma (NASDAQ:NVCT) enters agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1.93M shares at a price of $8.25 per share. Gross proceeds are expected to be ~$15.9M. Closing of the private placement is expected to occur on or about July 29, 2022.
Analysis Article • May 04

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Ron Bentsur's remuneration changed compared to Nuvectis Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$30m

Dec 31 2025US$3mUS$654k

-US$29m

Sep 30 2025n/an/a

-US$28m

Jun 30 2025n/an/a

-US$22m

Mar 31 2025n/an/a

-US$20m

Dec 31 2024US$1mUS$634k

-US$19m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023US$3mUS$615k

-US$22m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$2mUS$420k

-US$19m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$384kn/a

-US$13m

Compensation vs Market: Ron's total compensation ($USD2.59M) is about average for companies of similar size in the US market ($USD2.45M).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.

CEO

Ron Bentsur (60 yo)

6yrs
Tenure
US$2,588,526
Compensation

Mr. Ron Bentsur, M.B.A. is a Co-Founder of Nuvectis Pharma, Inc. on July 27, 2020 and serves as its Chairman, Chief Executive Officer and President since 2020. He has been Advisor of UroGen Pharma Ltd. sin...

Leadership Team

NamePositionTenureCompensationOwnership
Ron Bentsur
Co-Founder6yrsUS$2.59m11.7%
$ 70.0m
Enrique Poradosu
Co-Founder6yrsUS$1.59m5.73%
$ 34.3m
Shay Shemesh
Co-Founder6yrsUS$1.59m5.69%
$ 34.1m
Michael Carson
Vice President of Finance4.3yrsno data0.63%
$ 3.8m
6.0yrs
Average Tenure
54.5yo
Average Age

Experienced Management: NVCT's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ron Bentsur
Co-Founder6.5yrsUS$2.59m11.7%
$ 70.0m
James Oliviero
Independent Director5yrsUS$999.66k0.39%
$ 2.3m
Matthew Kaplan
Independent Director4.8yrsUS$989.66k0.51%
$ 3.0m
Juan Sanchez
Independent Directorless than a yearUS$191.00k0.36%
$ 2.2m
Paul Workman
Member of Scientific Advisory Board3.8yrsno datano data
Kenneth Hoberman
Independent Director5yrsUS$999.66k0.53%
$ 3.2m
Shannon Westin
Member of Scientific Advisory Board3.8yrsno datano data
4.8yrs
Average Tenure
58yo
Average Age

Experienced Board: NVCT's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 05:04
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvectis Pharma, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
I-Eh JenLaidlaw & Company (UK) Ltd
Christopher LiuLucid Capital Markets